MedTrace Logo

A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.

NCT01958957 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6300

Last updated 2014-12-24

No results posted yet for this study

Summary

The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.

Conditions

Interventions

DRUG

Ginkgolides Meglumine Injection

25mg, intravenous drip, once a day. Number of Cycles: 14 days.

Sponsors & Collaborators

  • Beijing Bionovo Medicine Development Co., Ltd.

    collaborator OTHER

  • Jiangsu Kanion Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Gao Ying, Doctor · Dongzhimen Hospital, Beijing

  • Zhou Li · Dongzhimen Hospital, Beijing

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01958957 on ClinicalTrials.gov